Harada K, Van de Water J, Leung P S, Coppel R L, Nakanuma Y, Gershwin M E
Division of Rheumatology, Allergy and Clinical Immunology, University of California, Davis 95616, USA.
Hepatology. 1997 Jan;25(1):27-32. doi: 10.1002/hep.510250106.
Pyruvate dehydrogenase-E2, or a cross-reactive molecule, has been shown by a variety of immunohistochemical methods to be present in increased amounts in biliary epithelial cells (BEC) in primary biliary cirrhosis (PBC). In this study, to further understand the nature of the immunoreactive molecule in BEC, we examined the expression of pyruvate dehydrogenase complex-E2 (PDC-E2) messenger RNA (mRNA) and PDC-E2 protein in sections of livers from patients and controls to help identify the molecule found in BEC. We performed in situ hybridization using an antisense probe against the major epitope of PDC-E2. The data were very striking and suggested that there was no increased production of PDC-E2 in BEC. For example, in livers from patients with PBC, PDC-E2 mRNA was found in periportal hepatocytes in 16 of 17 cases (94%). In contrast, interlobular bile ducts and septal bile ducts had detectable levels of PDC-E2 mRNA in only 1 of 17 (6%) and 3 of 8 (38%) cases, respectively. Interestingly, proliferating bile ductules contained detectable levels of mRNA in 12 of 15 cases (80%). In control liver, periportal hepatocytes were positive in 15 of 17 cases (88%). Interlobular bile ducts, septal bile ducts, and proliferating bile ductules expressed mRNA signals in 4 of 17 (24%), 2 of 10 (20%), and 14 of 16 (88%), respectively. When formalin-fixed, paraffin-embedded sections were examined by immunohistochemical staining with anti-PDC-E2 monoclonal antibody (mAb) C355.1, the interlobular bile ducts showed typical aberrant apical staining in all 10 PBC cases, but 0 of 9 liver controls. Periportal hepatocytes, proliferating bile ductules and infiltrating mononuclear cells stained with C355.1 but in a characteristic mitochondrial staining pattern. The presence of a PDC-E2-like molecule recognized by C355.1 is not reflected by the expression levels of PDC-E2 mRNA in the BEC of patients with PBC.
丙酮酸脱氢酶-E2或一种交叉反应性分子,已通过多种免疫组织化学方法显示在原发性胆汁性肝硬化(PBC)患者的胆管上皮细胞(BEC)中含量增加。在本研究中,为了进一步了解BEC中免疫反应性分子的性质,我们检测了患者和对照肝脏切片中丙酮酸脱氢酶复合物-E2(PDC-E2)信使核糖核酸(mRNA)和PDC-E2蛋白的表达,以帮助鉴定在BEC中发现的分子。我们使用针对PDC-E2主要表位的反义探针进行原位杂交。数据非常惊人,表明BEC中PDC-E2的产生没有增加。例如,在PBC患者的肝脏中,17例中有16例(94%)的门周肝细胞中发现了PDC-E2 mRNA。相比之下,小叶间胆管和间隔胆管中分别只有17例中的1例(6%)和8例中的3例(38%)检测到可检测水平的PDC-E2 mRNA。有趣的是,在15例中的12例(80%)增生性胆小管中检测到可检测水平的mRNA。在对照肝脏中,17例中的15例(88%)门周肝细胞呈阳性。小叶间胆管、间隔胆管和增生性胆小管中分别有17例中的4例(24%)、10例中的2例(20%)和16例中的14例(88%)表达mRNA信号。当用抗PDC-E2单克隆抗体(mAb)C355.1对福尔马林固定、石蜡包埋的切片进行免疫组织化学染色时,在所有10例PBC病例中,小叶间胆管均显示典型的异常顶端染色,但9例肝脏对照中均未出现。门周肝细胞、增生性胆小管和浸润的单核细胞用C355.1染色,但呈特征性的线粒体染色模式。PBC患者BEC中被C355.1识别的类PDC-E2分子的存在并未由PDC-E2 mRNA的表达水平反映出来。